Susmed (TSE:4263) ROC (Joel Greenblatt) %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
75 GF Score
Price 円719.00
GF Value 円847.12
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Susmed ROC (Joel Greenblatt) %?

Susmed TSE:4263 +1.27% 75 ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4263 with a GF Score™ of 75/100 and a GF Value™ of 円847.12 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 666 Healthcare Providers & Services companies, Susmed ranks worse than 150150% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Susmed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Susmed's ROC (Joel Greenblatt) % or its related term are showing as below:

TSE:4263's ROC (Joel Greenblatt) % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 12.47
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Susmed's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Susmed  (TSE:4263) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Susmed ROC (Joel Greenblatt) % Related Terms


Susmed ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Susmed's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed ROC (Joel Greenblatt) % Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Susmed Quarterly Data
Jun20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4263 vs VEEV, BTSG, TEM: ROC (Joel Greenblatt) % Comparison

For the Health Information Services subindustry, Susmed's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Susmed ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Susmed's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Susmed's ROC (Joel Greenblatt) % falls into.


TSE:4263
75GF Score
Susmed Inc TSE:4263
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Susmed ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.786 + 1.093 + 61.544000000001) - (71.024 + 0 + 50.228)
=-42.828999999999

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.504 + 0.104 + 74.237999999999) - (67.566 + 0 + 49.697)
=-25.417000000001

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Susmed for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0 + max(-42.828999999999, 0)) + (0 + max(-25.417000000001, 0)) )/ 1 )
=0/( ( 0 + 0 )/ 1 )
=0/0
= %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Susmed (TSE:4263) has a ROC (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #999999 out of 666 companies in the Healthcare Providers & Services industry.
Is Susmed's ROC (Joel Greenblatt) % too high?
Susmed's current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Susmed ranks #999999 out of 666 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Susmed has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's ROC (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #999999 out of 666 companies for ROC (Joel Greenblatt) %. This places Susmed in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.47, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Susmed and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円847.12, compared to a current price of 円719.00 — trading 15.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 0.00%. Susmed's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Susmed (TSE:4263), the current ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円719.00 is trading 15.1% below its estimated GF Value™ of 円847.12. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • ROC (Joel Greenblatt) %: 0.00%
  • GF Value™: 円847.12 vs. price of 円719.00 (15.1% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
75GF Score

Get the complete analysis for TSE:4263

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円719.00
Price
円847.12
GF Value